Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001

References

• Hartikainen S, Rahkonen T, Kautiainen H, Sulkava R. Use of psychotropics among home-dwelling nondemented and demented elderly. International Journal of Geriatric Psychiatry 2003; 18: 1135–1141
   PubMed Web of Science ®Google Scholar
• Brodaty H, Draper B, Saab D. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. International Journal of Geriatric Psychiatry 2001; 16: 504–512
   PubMed Web of Science ®Google Scholar
• Snowdon J. A follow-up survey of psychotropic drug use in Sydney nursing homes. Medical Journal of Australia 1999; 170: 299–301
   PubMed Web of Science ®Google Scholar
• Bronskill S E, Anderson G M, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose and specialist contact. Journal of the American Geriatric Society 2004; 52: 749–755
   PubMed Web of Science ®Google Scholar
• De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioural disturbances in patients with Alzheimer’s disease. International Journal of Geriatric Psychiatry 2004; 19: 115–126
   PubMed Web of Science ®Google Scholar
• Deberdt W G, Dysken M W, Rappaport S A, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. American Journal of Geriatric Psychiatry 2005; 13: 722–730
   PubMed Web of Science ®Google Scholar
• Sink K M, Holden K F, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. Journal of the American Medical Association 2005; 293: 596–608
   PubMed Web of Science ®Google Scholar
• Jeste D V, Okamoto A, Napolitano J, Kane J, Martinez R A. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. American Journal of Psychiatry 2000; 157: 1150–1155
   PubMedGoogle Scholar
• Lieberman J A, Tollefson G, Tohen M, Green A I. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomised, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 2003; 160: 1396–1402
   PubMed Web of Science ®Google Scholar
• Wooltorton E. Risperidone (risperdal): increased rate of cerebrovascular events in dementia trials. Canadian Medical Association Journal 2002; 167: 1269–1270
   PubMed Web of Science ®Google Scholar
• Schneider L S, Dagerman K S, Inse P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 2005; 294: 1934–1943
   PubMed Web of Science ®Google Scholar
• Committee on Safety in Medicines. Atypical antipsychotic drugs and stroke 2004, [cited 21 November 2005]. Available at: http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019488.pdf
   Google Scholar
• Schneider L S, Tariot P N, Lyketsos C G, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): alzheimers disease trial methodology. American Journal of Geri Psychiatry 2001; 9: 340–360
   Google Scholar
• Gill S S, Rochon P A, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. British Medical Journal 2005; 330: 445
   PubMed Web of Science ®Google Scholar
• Wang P S, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional versus atypical antipsychotic medications. New England Journal of Medicine 2005; 353: 2335–2341
   PubMed Web of Science ®Google Scholar
• Liperoti R, Gambassi G, Lapane K L, et al. Conventional and atypical antipsychotics and the risk of hospitalisation for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine 2005; 165: 696–701
   PubMed Web of Science ®Google Scholar
• Nasrallah H A, White T, Nasrallah A. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. American Journal of Geriatric Psychiatry 2004; 12: 437–439
   PubMedGoogle Scholar
• Brodaty H, Ames D, Snowdon J, et al. A randomized placebocontrolled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Journal of Clinical Psychiatry 2003; 64: 134–143
   PubMed Web of Science ®Google Scholar
• Cavazzoni P, Young C, Polzer J, et al. Incidence of cerebrovascular adverse events and mortality during antipsychotic clinical trials of elderly patients with dementia. Eli Lilly, Indianapolis, IN 2004, NCDEU 2004
   Google Scholar
• Tisdale J E, Rasty S, Padhi I D, Sharma N D, Rosman H. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes. Journal of Clinical Pharmacology 2001; 42: 577–579
   Google Scholar
• Casarett D J, Inouye S K. Diagnosis and management of delirium near the end of life. Annals of International Medicine 2001; 135: 32–40
   PubMed Web of Science ®Google Scholar
• Ray W A. Evaluating medication effects outside of clinical trials: new user design. American Journal of Epidemiology 2003; 158: 915–920
   PubMed Web of Science ®Google Scholar
• Ray W A, Stein C M, Daugherty J R, Hall K, Arbogast P G, Griffin M R. Cox-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071– 1073
   PubMed Web of Science ®Google Scholar
• Ray W A. Observational studies of drug and mortality. New England Journal of Medicine 2005; 353: 2319–2321
   PubMed Web of Science ®Google Scholar
• Herrmann N, Mamdani M, Lanctot K L. Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry 2004; 161: 1113–1115
   PubMed Web of Science ®Google Scholar
• Ray W A, Meredith S, Thapa P B, Meador K G. Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry 2001; 58: 1161–1168
   PubMed Web of Science ®Google Scholar
• Report of the Working Party of the Royal College of Psychiatrists’ Psychopharmacology Sub-Group. The association between antipsychotic drugs and sudden death. Royal College of Psychiatrists, London 1997
   Google Scholar